Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 08, 2016 16:05 ET | Source: SCYNEXIS, Inc.

SCYNEXIS, Inc. Announces Positive Results in its Proof-of-Concept Phase 2 Study of SCY-078, the First Member of a Novel Class of Glucan Synthase Inhibitors

Confirmation of Clinically Relevant Antifungal Activity of SCY-078 in Patients with Candida Infections Company to Host a Conference Call Today at 5:00pm ET to Discuss Results JERSEY CITY, N.J.,...
May 13, 2016 08:00 ET | Source: SCYNEXIS, Inc.

SCYNEXIS, Inc. Receives Orphan Drug Designation for SCY-078 for the Treatment of Invasive Candida Infections

JERSEY CITY, N.J., May 13, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug...
May 09, 2016 09:25 ET | Source: SCYNEXIS, Inc.

SCYNEXIS, Inc. Reports First Quarter 2016 Financial Results and Provides Company Update

JERSEY CITY, N.J., May 09, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today reported financial results for the quarter ended March 31, 2016, and provided an...
April 19, 2016 09:15 ET | Source: SCYNEXIS, Inc.

SCYNEXIS Receives Designation as a Small and Medium Enterprise by the European Medicines Agency

JERSEY CITY, N.J., April 19, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) announced today that the Company has been granted Small and Medium Sized Enterprise...
April 15, 2016 09:00 ET | Source: SCYNEXIS, Inc.

SCYNEXIS Presents Data Supporting the Activity of its Lead Antifungal Drug Candidate SCY-078 Against Antifungal-resistant Candida Strains at the 13th ASM Conference on Candida and Candidiasis

JERSEY CITY, N.J., April 15, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) announced today that results of three nonclinical studies of the company’s lead clinical...
April 06, 2016 16:30 ET | Source: SCYNEXIS, Inc.

SCYNEXIS, Inc. to Present at the 15th Annual Needham Healthcare Conference

JERSEY CITY, N.J., April 06, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the 15th Annual Needham Healthcare...
April 06, 2016 09:20 ET | Source: SCYNEXIS, Inc.

SCYNEXIS to Present Data from Lead Antifungal Drug Candidate SCY-078 at 13th ASM Conference on Candida and Candidiasis

JERSEY CITY, N.J., April 06, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) announced today that results of three nonclinical studies of the company’s lead clinical...
March 07, 2016 08:36 ET | Source: SCYNEXIS, Inc.

SCYNEXIS, Inc. Reports Full Year 2015 Financial Results and Provides Company Update

JERSEY CITY, N.J., March 07, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today reported financial results for the year ended December 31, 2015, and provided an...
February 29, 2016 17:30 ET | Source: SCYNEXIS, Inc.

SCYNEXIS, Inc. to Present at the Cowen and Company 36th Annual Health Care Conference

JERSEY CITY, N.J., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the Cowen and Company 36th Annual Health...
February 03, 2016 09:05 ET | Source: SCYNEXIS, Inc.

SCYNEXIS, Inc. to Present at Upcoming Investor Conferences

JERSEY CITY, N.J., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the following upcoming investor...